Physician profile
Sarah E Hall
NPI 1841743788
$2,627.05
in general payments reported to CMS, 2019-2025
21 companies · $263 in 2025
The $263 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $422 · 2022: $490 · 2023: $313 · 2024: $1,139 · 2025: $263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,715.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,714.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $510.51 | 2021-2025 | Spravato, Xarelto |
| E.R. Squibb & Sons, L.L.C. | $376.50 | 2021-2025 | Cobenfy, Camzyos |
| Teva Pharmaceuticals USA, INC. | $254.86 | 2024-2025 | Austedo Xr, Uzedy |
| Abbvie INC. | $243.86 | 2023-2025 | |
| Corium, LLC | $184.55 | 2024-2025 | Azstarys |
| Axsome Therapeutics, INC. | $153.88 | 2023-2025 | Auvelity |
| Supernus Pharmaceuticals, INC. | $146.25 | 2024 | Qelbree |
| Angiodynamics, INC. | $129.17 | 2023 | Auryon Laser System 100-120 Vac |
| Novartis Pharmaceuticals Corporation | $126.97 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $115.76 | 2022-2024 | Caplyta |
| Lundbeck LLC | $85.80 | 2024 | Abilify Maintena, Rexulti |
| Otsuka America Pharmaceutical, INC. | $59.58 | 2024-2025 | Rexulti |
| Ironshore Pharmaceuticals INC. | $52.64 | 2023-2024 | Jornay Pm |
| Astrazeneca Pharmaceuticals LP | $40.21 | 2021-2022 | |
| Indivior INC. | $36.11 | 2023-2024 | Sublocade |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $23.84 | 2023 | |
| Alkermes, INC. | $19.24 | 2023 | Aristada, Lybalvi |
| Collegium Pharmaceutical, INC. | $18.91 | 2025 | Jornay Pm |
| Merck Sharp & Dohme LLC | $17.87 | 2021 | |
| Noven Therapeutics, LLC | $16.74 | 2024 | Secuado, Xelstrym |
| Takeda Pharmaceuticals U.S.A., INC. | $13.80 | 2024 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.